Moderna has priced its initial public offering (IPO) of 26 million common stock shares at $23 a share, with the aim of raising $604.3m.

Underwriters will be granted a 30-day option to purchase an additional 3.9 million common stock shares at the IPO price excluding underwriting discounts and commissions.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Oddo BHF SCA, Oppenheimer & Co, Needham & Company, and Chardan are the co-managers for the offering.

Moderna is a clinical-stage biopharmaceutical company based in the US.

Oxford BioTherapeutics has expanded its collaboration with WuXi Biologics to research, develop and commercialise five new bispecific antibodies for cancer treatment using the latter’s WuXiBody™ platform.

WuXi will receive up to $450m upfront, as well as milestone payments.

Oxford’s expertise in drug target discovery and development will be integrated with WuXi’s bispecific antibodies development to create and commercialise an antibody-based cancer therapeutics portfolio.

Oxford Biotherapeutics is a biotechnology company based in the UK, while WuXi Biologics is a pharmaceutical manufacturing company based in the China.

CBT Pharmaceuticals aims to improve patient enrolment in its ongoing clinical trial of the c-Met inhibitor CBT-101 in cancer patients with c-Met dysregulation after partnering with Strata Oncology.

“Biohaven has announced an underwritten public offering of three million common shares.”

Advanced cancer patients with c-Met dysregulation identified through the Strata trial, including those with non-small cell lung cancer and other solid tumours, will be enrolled in the clinical trial.

CBT Pharmaceuticals is a biopharmaceutical company based in the US, while Strata Oncology is a company specialising in the provision of a precision oncology platform.

HiFiBiO Therapeutics has formed a joint venture with Dr Vikas Sukhatme, the Dean of Emory University School of Medicine.

The JV will be named Victa Biotherapeuticsa and will focus on the discovery and development of antibody-based cancer therapeutics.

Victa Biotherapeutics will perform the validation of molecules that were discovered by Dr Sukhatme and team at the Beth Israel Deaconess Medical Center (BIDMC).

The company is also eligible to gain an exclusive license to the intellectual property of the drug molecule targets from BIDMC.

HiFiBiO Therapeutics is a biotherapeutics company based in France.

Biohaven has announced an underwritten public offering of three million common shares.

The underwriters will also be granted an additional 450,000 shares at the public offer price.

Goldman Sachs & Co and Piper Jaffray & Co are managing the offering.

Biohaven is a biopharmaceutical company based in the US.